Company intelligence / Profile preview
Ophthalogix
Boston, Massachusetts, United Statesophthalogix.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Ophthalogix is a biotechnology company focused on developing innovative therapies for retinal diseases. The company's primary focus is on creating long-acting, sustained-release formulations of established and novel compounds to treat conditions such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). By utilizing advanced drug delivery technologies, Ophthalogix aims to reduce the treatment burden for patients who currently require frequent intravitreal injections. Their lead programs involve small molecule inhibitors targeting vascular endothelial growth factor (VEGF) pathways.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Ophthalogix.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ophthalogix.